The global market for Viral Vector-Based Cell & Gene Therapy CDMO was valued at US$ 142 million in the year 2024 and is projected to reach a revised size of US$ 325 million by 2031, growing at a CAGR of 12.9% during the forecast period.

Viral Vector-Based Cell & Gene Therapy CDMO Market

Viral vector-based cell and gene therapy CDMO refers to a contract research and development and production organization (CDMO) that focuses on providing professional R&D and production services for viral vector-based cell and gene therapy products to biopharmaceutical companies. These services cover everything from the design and optimization of viral vectors to large-scale production in accordance with GMP (Good Manufacturing Practice) standards, as well as product quality control and safety assurance.

North American market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Viral Vector-Based Cell & Gene Therapy CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Viral Vector-Based Cell & Gene Therapy CDMO in Gene Therapy is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Viral Vector-Based Cell & Gene Therapy CDMO include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, Exothera, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Viral Vector-Based Cell & Gene Therapy CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector-Based Cell & Gene Therapy CDMO.

The Viral Vector-Based Cell & Gene Therapy CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vector-Based Cell & Gene Therapy CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Viral Vector-Based Cell & Gene Therapy CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Viral Vector-Based Cell & Gene Therapy CDMO Market Report

Report Metric	Details
Report Name	Viral Vector-Based Cell & Gene Therapy CDMO Market
Accounted market size in year	US$ 142 million
Forecasted market size in 2031	US$ 325 million
CAGR	12.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Adeno-associated Viral Adenoviral Lentiviral Retroviral
Segment by Application	Gene Therapy Cell Therapy Vaccine Development
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, Exothera
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector-Based Cell & Gene Therapy CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Viral Vector-Based Cell & Gene Therapy CDMO Market growing?

Ans: The Viral Vector-Based Cell & Gene Therapy CDMO Market witnessing a CAGR of 12.9% during the forecast period 2025-2031.

What is the Viral Vector-Based Cell & Gene Therapy CDMO Market size in 2031?

Ans: The Viral Vector-Based Cell & Gene Therapy CDMO Market size in 2031 will be US$ 325 million.

Who are the main players in the Viral Vector-Based Cell & Gene Therapy CDMO Market report?

Ans: The main players in the Viral Vector-Based Cell & Gene Therapy CDMO Market are AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, Exothera

What are the Application segmentation covered in the Viral Vector-Based Cell & Gene Therapy CDMO Market report?

Ans: The Applications covered in the Viral Vector-Based Cell & Gene Therapy CDMO Market report are Gene Therapy, Cell Therapy, Vaccine Development

What are the Type segmentation covered in the Viral Vector-Based Cell & Gene Therapy CDMO Market report?

Ans: The Types covered in the Viral Vector-Based Cell & Gene Therapy CDMO Market report are Adeno-associated Viral, Adenoviral, Lentiviral, Retroviral

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Adeno-associated Viral

1.2.3 Adenoviral

1.2.4 Lentiviral

1.2.5 Retroviral

1.3 Market by Application

1.3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Gene Therapy

1.3.3 Cell Therapy

1.3.4 Vaccine Development

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Perspective (2020-2031)

2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Growth Trends by Region

2.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size by Region (2020-2025)

2.2.3 Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Region (2026-2031)

2.3 Viral Vector-Based Cell & Gene Therapy CDMO Market Dynamics

2.3.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends

2.3.2 Viral Vector-Based Cell & Gene Therapy CDMO Market Drivers

2.3.3 Viral Vector-Based Cell & Gene Therapy CDMO Market Challenges

2.3.4 Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Viral Vector-Based Cell & Gene Therapy CDMO Players by Revenue

3.1.1 Global Top Viral Vector-Based Cell & Gene Therapy CDMO Players by Revenue (2020-2025)

3.1.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Top Viral Vector-Based Cell & Gene Therapy CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Viral Vector-Based Cell & Gene Therapy CDMO Revenue

3.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Concentration Ratio

3.4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Viral Vector-Based Cell & Gene Therapy CDMO Revenue in 2024

3.5 Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO Head office and Area Served

3.6 Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO, Product and Application

3.7 Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Viral Vector-Based Cell & Gene Therapy CDMO Breakdown Data by Type

4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size by Type (2020-2025)

4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Type (2026-2031)

5 Viral Vector-Based Cell & Gene Therapy CDMO Breakdown Data by Application

5.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size by Application (2020-2025)

5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2020-2031)

6.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)

6.4 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2020-2031)

7.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)

7.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2020-2031)

8.2 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2020-2031)

9.2 Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)

9.4 Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2020-2031)

10.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AGC Biologics

11.1.1 AGC Biologics Company Details

11.1.2 AGC Biologics Business Overview

11.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Introduction

11.1.4 AGC Biologics Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

11.1.5 AGC Biologics Recent Development

11.2 Lonza

11.2.1 Lonza Company Details

11.2.2 Lonza Business Overview

11.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Introduction

11.2.4 Lonza Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

11.2.5 Lonza Recent Development

11.3 Charles River Laboratories

11.3.1 Charles River Laboratories Company Details

11.3.2 Charles River Laboratories Business Overview

11.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Introduction

11.3.4 Charles River Laboratories Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

11.3.5 Charles River Laboratories Recent Development

11.4 Thermo Fisher Scientific

11.4.1 Thermo Fisher Scientific Company Details

11.4.2 Thermo Fisher Scientific Business Overview

11.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Introduction

11.4.4 Thermo Fisher Scientific Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

11.4.5 Thermo Fisher Scientific Recent Development

11.5 SK pharmteco

11.5.1 SK pharmteco Company Details

11.5.2 SK pharmteco Business Overview

11.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Introduction

11.5.4 SK pharmteco Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

11.5.5 SK pharmteco Recent Development

11.6 Exothera

11.6.1 Exothera Company Details

11.6.2 Exothera Business Overview

11.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Introduction

11.6.4 Exothera Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

11.6.5 Exothera Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Charles River Laboratories

Thermo Fisher Scientific

SK pharmteco

Exothera

List of Tables

Table 1. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Adeno-associated Viral

Table 3. Key Players of Adenoviral

Table 4. Key Players of Lentiviral

Table 5. Key Players of Retroviral

Table 6. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2020-2025)

Table 10. Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2026-2031)

Table 12. Viral Vector-Based Cell & Gene Therapy CDMO Market Trends

Table 13. Viral Vector-Based Cell & Gene Therapy CDMO Market Drivers

Table 14. Viral Vector-Based Cell & Gene Therapy CDMO Market Challenges

Table 15. Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints

Table 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Players (2020-2025)

Table 18. Global Top Viral Vector-Based Cell & Gene Therapy CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Cell & Gene Therapy CDMO as of 2024)

Table 19. Ranking of Global Top Viral Vector-Based Cell & Gene Therapy CDMO Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Viral Vector-Based Cell & Gene Therapy CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO, Headquarters and Area Served

Table 22. Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO, Product and Application

Table 23. Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2020-2025)

Table 27. Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2026-2031)

Table 29. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2020-2025)

Table 31. Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2026-2031)

Table 33. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 48. AGC Biologics Company Details

Table 49. AGC Biologics Business Overview

Table 50. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product

Table 51. AGC Biologics Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025) & (US$ Million)

Table 52. AGC Biologics Recent Development

Table 53. Lonza Company Details

Table 54. Lonza Business Overview

Table 55. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product

Table 56. Lonza Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025) & (US$ Million)

Table 57. Lonza Recent Development

Table 58. Charles River Laboratories Company Details

Table 59. Charles River Laboratories Business Overview

Table 60. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product

Table 61. Charles River Laboratories Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025) & (US$ Million)

Table 62. Charles River Laboratories Recent Development

Table 63. Thermo Fisher Scientific Company Details

Table 64. Thermo Fisher Scientific Business Overview

Table 65. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product

Table 66. Thermo Fisher Scientific Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025) & (US$ Million)

Table 67. Thermo Fisher Scientific Recent Development

Table 68. SK pharmteco Company Details

Table 69. SK pharmteco Business Overview

Table 70. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product

Table 71. SK pharmteco Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025) & (US$ Million)

Table 72. SK pharmteco Recent Development

Table 73. Exothera Company Details

Table 74. Exothera Business Overview

Table 75. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product

Table 76. Exothera Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025) & (US$ Million)

Table 77. Exothera Recent Development

Table 78. Research Programs/Design for This Report

Table 79. Key Data Information from Secondary Sources

Table 80. Key Data Information from Primary Sources

Table 81. Authors List of This Report

List of Figures

Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Picture

Figure 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type: 2024 VS 2031

Figure 4. Adeno-associated Viral Features

Figure 5. Adenoviral Features

Figure 6. Lentiviral Features

Figure 7. Retroviral Features

Figure 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application: 2024 VS 2031

Figure 10. Gene Therapy Case Studies

Figure 11. Cell Therapy Case Studies

Figure 12. Vaccine Development Case Studies

Figure 13. Viral Vector-Based Cell & Gene Therapy CDMO Report Years Considered

Figure 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region: 2024 VS 2031

Figure 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Players in 2024

Figure 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Viral Vector-Based Cell & Gene Therapy CDMO Revenue in 2024

Figure 20. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2020-2031)

Figure 22. United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2020-2031)

Figure 26. Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2020-2031)

Figure 34. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2020-2031)

Figure 42. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2020-2031)

Figure 46. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. AGC Biologics Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

Figure 50. Lonza Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

Figure 51. Charles River Laboratories Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

Figure 52. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

Figure 53. SK pharmteco Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

Figure 54. Exothera Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2020-2025)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions